Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapy stocks.

Immunotherapy Stocks Recent News

Date Stock Title
May 15 FBIOP Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15 NBTX NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
May 15 FBIOP Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15 FBIOP AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
May 15 ATNM Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
May 15 FBIOP Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14 ATNM Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the ...
May 14 NBTX NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
May 14 CADL Candel Therapeutics GAAP EPS of -$0.28
May 14 XLO Xilio Therapeutics GAAP EPS of -$0.62
May 14 FBIOP Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
May 14 CADL Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14 XLO Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 13 FBIOP Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 13 FBIOP Fortress Biotech, Inc. 9.375% CUM PFD A goes ex dividend tomorrow
May 13 FBIOP Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13 ATNM Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
May 12 ATNM A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
May 11 IBRX ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 10 ALPN Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags